SGLT2i vs placebo
All‐cause mortality · CVD (ASCVD, HF, or both)
SGLT2i probably leads to lower all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
- Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes onlyOR 0.84 [0.74, 0.96]5 studies · 24962 participantsModerate